Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238921 | 1.00 | RECQL (0.37) | RECQLMAPTPOLBGAAKDM4E | |
| SCHEMBL8198326 | 0.88 | MAPT (0.42) | RECQLMAPTPOLBGAAKDM4E | |
| Clothianidine SCHEMBL14273626 | 0.84 | RECQL (0.39) | RECQLMAPTPOLBGAAKDM4E | |
| Clothianidine SCHEMBL237824 | 0.84 | RECQL (0.39) | RECQLMAPTPOLBGAAKDM4E | |
| Clothianidine SCHEMBL2413061 | 0.84 | RECQL (0.39) | RECQLMAPTPOLBGAAKDM4E | |
| Clothianidine SCHEMBL21214 | 0.84 | RECQL (0.39) | RECQLMAPTPOLBGAAKDM4E | |
| SCHEMBL8659276 | 0.82 | RECQL (0.38) | RECQLMAPTPOLBGAAKDM4E | |
| Clothianidine SCHEMBL15380758 | 0.82 | RECQL (0.38) | RECQLMAPTPOLBGAAKDM4E | |
| SCHEMBL8659282 | 0.82 | RECQL (0.38) | RECQLMAPTPOLBGAAKDM4E | |
| SCHEMBL13240173 | 0.81 | RECQL (0.42) | RECQLMAPTPOLBGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293733-B2 | Oil dispersions of nAChR binding neonicotinoids | GAT MICROENCAPSULATION AG (AT) | 2012-10-23 | — | — | US | disclosed |
| US-20120004104-A1 | OIL DISPERSIONS OF nAChR BINDING NEONICOTINOIDS | GAT MICROENCAPSULATION AG (AT) | 2012-01-05 | — | — | US | disclosed |
| EP-2225940-A1 | Oil dispersions of nAChR binding neonicotinoids | GAT Microencapsulation AG (AT) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004104-A1 | OIL DISPERSIONS OF nAChR BINDING NEONICOTINOIDS | CHRND, ITGAM, CHRM2 | RECQL 3472/4885MAPT 3809/4885POLB 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.